Skip to main content
Top
Published in: Current Infectious Disease Reports 5/2012

01-10-2012 | Sepsis (J Russell, Section Editor)

Immune Aspects of Sepsis and Hope for New Therapeutics

Authors: Steven P. LaRosa, Steven M. Opal

Published in: Current Infectious Disease Reports | Issue 5/2012

Login to get access

Abstract

Marked alterations of the innate and adaptive immune response follow invasive infection and generalized inflammatory states. If left unchecked, this state of immune dysregulation contributes to a myriad of maladaptive cellular responses that culminate in multiple organ dysfunction, septic shock, and lethality. The molecular details of the cell-signaling networks that underlie the pathophysiology of systemic inflammation and sepsis are now increasingly well understood. While a vigorous and effective immune response to invasive pathogens is essential for microbial clearance and host survival, nonresolving, generalized inflammation can induce diffuse endovascular damage, increased capillary permeability, coagulopathy, and widespread tissue damage. Current evidence indicates that a state of relative immune suppression often accompanies sepsis and might provide novel therapeutic options in some patients. An expanding number of potential therapeutic options are now in clinical development to reestablish control and promote resolution over sepsis-induced systemic inflammation and organ dysfunction.
Literature
1.
2.
go back to reference Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291–304.PubMedCrossRef Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291–304.PubMedCrossRef
3.
go back to reference •• Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi:10.1084/jem.20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences. •• Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi:10.​1084/​jem.​20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences.
4.
go back to reference • Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464(1):60–70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens. • Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464(1):60–70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens.
5.
go back to reference Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–403.PubMedCrossRef Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–403.PubMedCrossRef
6.
go back to reference Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef
8.
go back to reference Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–63.PubMedCrossRef Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257–63.PubMedCrossRef
9.
go back to reference Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875–84.PubMedCrossRef Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875–84.PubMedCrossRef
10.
go back to reference • Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.PubMedCrossRef • Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.PubMedCrossRef
11.
go back to reference Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24.PubMedCrossRef Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24.PubMedCrossRef
12.
13.
go back to reference Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880–2.PubMedCrossRef Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880–2.PubMedCrossRef
14.
15.
go back to reference Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1–15.CrossRef Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1–15.CrossRef
16.
go back to reference Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef
17.
go back to reference • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.PubMedCrossRef • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.PubMedCrossRef
18.
go back to reference Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.PubMedCrossRef Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–22.PubMedCrossRef
19.
go back to reference Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87–9.CrossRef Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87–9.CrossRef
20.
go back to reference •• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.PubMedCrossRef •• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.PubMedCrossRef
22.
go back to reference Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leuk Biol. 2010;88:779–89.CrossRef Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leuk Biol. 2010;88:779–89.CrossRef
23.
go back to reference •• Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871–82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.PubMedCrossRef •• Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871–82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.PubMedCrossRef
24.
25.
go back to reference Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327–36.PubMedCrossRef Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327–36.PubMedCrossRef
26.
go back to reference Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170–84.PubMedCrossRef Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170–84.PubMedCrossRef
27.
go back to reference Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRef Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRef
28.
go back to reference Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74.
29.
go back to reference • Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholine-synthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98–101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.CrossRef • Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholine-synthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98–101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.CrossRef
30.
go back to reference • Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.PubMedCrossRef • Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101–5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.PubMedCrossRef
31.
go back to reference Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659–64.PubMed Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659–64.PubMed
32.
go back to reference • Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.PubMedCrossRef • Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.PubMedCrossRef
33.
go back to reference Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef
34.
go back to reference Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163–9.PubMed Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163–9.PubMed
35.
go back to reference Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRef Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65.PubMedCrossRef
36.
go back to reference Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli- induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174–9.PubMedCrossRef Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli- induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174–9.PubMedCrossRef
37.
go back to reference Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309–14.PubMedCrossRef Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309–14.PubMedCrossRef
38.
go back to reference Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417–23.PubMedCrossRef Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417–23.PubMedCrossRef
39.
go back to reference • Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.PubMedCrossRef • Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.PubMedCrossRef
40.
go back to reference Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.CrossRef Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.CrossRef
41.
go back to reference Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271–81.PubMedCrossRef Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271–81.PubMedCrossRef
42.
go back to reference Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011. Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011.
44.
go back to reference Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393–9.PubMedCrossRef Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393–9.PubMedCrossRef
45.
go back to reference Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131–8.PubMedCrossRef Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131–8.PubMedCrossRef
46.
go back to reference Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123–30.PubMedCrossRef Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123–30.PubMedCrossRef
47.
go back to reference Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/б in septic shock. Am J Respir Crit Care Med. 2010;182:1506–15.PubMedCrossRef Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/б in septic shock. Am J Respir Crit Care Med. 2010;182:1506–15.PubMedCrossRef
48.
go back to reference • Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055–64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.PubMedCrossRef • Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055–64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.PubMedCrossRef
49.
go back to reference Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82:1687–93.PubMed Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82:1687–93.PubMed
50.
go back to reference Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.PubMedCrossRef Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.PubMedCrossRef
51.
go back to reference Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97–104.PubMedCrossRef Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97–104.PubMedCrossRef
52.
53.
go back to reference • Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672–82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.PubMedCrossRef • Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672–82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.PubMedCrossRef
54.
go back to reference Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–10.PubMedCrossRef Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–10.PubMedCrossRef
55.
go back to reference Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–92.PubMedCrossRef Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–92.PubMedCrossRef
56.
go back to reference Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770–7.PubMedCrossRef Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770–7.PubMedCrossRef
57.
go back to reference Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185–91.PubMedCrossRef Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185–91.PubMedCrossRef
58.
go back to reference Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768–79.PubMedCrossRef Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768–79.PubMedCrossRef
59.
go back to reference Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409.
60.
go back to reference Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–40.PubMedCrossRef Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233–40.PubMedCrossRef
61.
go back to reference Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–9.PubMedCrossRef Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–9.PubMedCrossRef
62.
go back to reference Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131–8.PubMedCrossRef Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131–8.PubMedCrossRef
63.
go back to reference Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786–96.CrossRef Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786–96.CrossRef
64.
go back to reference • Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379–85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.PubMedCrossRef • Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379–85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.PubMedCrossRef
65.
go back to reference Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–57.PubMedCrossRef Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047–57.PubMedCrossRef
66.
go back to reference Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press.
Metadata
Title
Immune Aspects of Sepsis and Hope for New Therapeutics
Authors
Steven P. LaRosa
Steven M. Opal
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2012
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0276-2

Other articles of this Issue 5/2012

Current Infectious Disease Reports 5/2012 Go to the issue

Sepsis (J Russell, Section Editor)

Cardiovascular Management of Septic Shock in 2012

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

Prevention of Surgical Site Infections in Bone and Joint Procedures

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Subcutaneous Fungal Infections

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.